What Is the Life Expectancy for Mesothelioma?

Median Survival by Stage

Stage at diagnosis is the single most important factor affecting mesothelioma life expectancy. Data from the National Cancer Institute's SEER program shows a clear correlation between stage and survival.

Stage I (localized): Median survival of approximately 21 months. The tumor is confined to one side of the pleura and has not spread to lymph nodes. Patients at this stage are most likely to be candidates for curative-intent surgery.

Stage II (locally advanced): Median survival of approximately 19 months. The cancer has begun to spread to nearby structures but remains on one side of the chest. Surgery is still an option for many stage II patients.

Stage III (advanced): Median survival of approximately 16 months. The tumor has spread to lymph nodes or invaded nearby organs. Treatment focuses on controlling the disease and maintaining quality of life, though some patients may still qualify for surgery.

Stage IV (metastatic): Median survival of approximately 12 months. The cancer has spread to distant organs. Treatment at this stage is primarily palliative, aimed at relieving symptoms and extending life as much as possible.

Cell Type and Prognosis

Mesothelioma tumors are classified by their cellular composition, and this classification significantly affects prognosis. There are three main cell types.

Epithelioid is the most common type, accounting for 50 to 70% of cases. It carries the best prognosis because these cells divide more slowly and respond better to treatment. Median survival for epithelioid mesothelioma ranges from 12 to 24 months.

Sarcomatoid accounts for 10 to 20% of cases and has the poorest prognosis. Sarcomatoid cells are more aggressive, spread faster, and are more resistant to treatment. Median survival is typically 6 to 12 months.

Biphasic (mixed) contains both epithelioid and sarcomatoid cells and accounts for 20 to 30% of cases. Prognosis depends on the ratio of cell types — a higher proportion of epithelioid cells is associated with better outcomes. Median survival generally falls between 10 and 16 months.

Factors That Affect Prognosis

Beyond stage and cell type, several additional factors influence mesothelioma life expectancy:

• Age: Younger patients (under 65) tend to tolerate aggressive treatment better and have longer survival times
• Gender: Women with mesothelioma have statistically better outcomes than men, though the reasons are not fully understood
• Overall health: Patients with good performance status (able to carry out daily activities) respond better to treatment
• Mesothelioma type: Peritoneal mesothelioma treated with surgery and heated chemotherapy (HIPEC) has a notably better prognosis than pleural mesothelioma, with 5-year survival rates exceeding 50% in select patients
• Blood markers: Lower levels of certain biomarkers, such as mesothelin and fibulin-3, may indicate a better prognosis

5-Year Survival Rates

According to the American Cancer Society, the overall 5-year relative survival rate for mesothelioma is approximately 12%. However, this number encompasses all stages and cell types. When broken down by stage:

• Localized disease: Approximately 18% 5-year survival
• Regional spread: Approximately 12% 5-year survival
• Distant metastasis: Approximately 7% 5-year survival

It is important to understand that these statistics are based on historical data and may not reflect the most recent treatment advances, including immunotherapy combinations that have shown improved outcomes in clinical trials.

How Treatment Improves Outcomes

Patients who receive active treatment consistently survive longer than those who receive supportive care alone. Multimodal treatment — combining surgery, chemotherapy, and radiation — has produced the best results for eligible patients.

The 2020 FDA approval of nivolumab plus ipilimumab (Opdivo + Yervoy) for unresectable pleural mesothelioma marked a significant advance. In the CheckMate 743 trial, this immunotherapy combination improved median overall survival to 18.1 months compared to 14.1 months with standard chemotherapy.

For peritoneal mesothelioma, cytoreductive surgery combined with HIPEC has produced some of the most encouraging outcomes, with median survival exceeding 50 months at specialized treatment centers. These results underscore the importance of seeking treatment at centers with mesothelioma expertise.

Long-Term Survivors

While mesothelioma statistics can seem discouraging, long-term survivors do exist. Some patients have lived 5, 10, or even 15 or more years after diagnosis. Common characteristics among long-term survivors include early-stage diagnosis, epithelioid cell type, younger age, treatment at a specialized mesothelioma center, and participation in clinical trials.

Individual outcomes vary significantly from statistical averages. A prognosis is a general estimate, not a definitive prediction. Many factors — including future treatment advances and individual biology — can influence actual survival.